Allergy Therapeutics plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AGY.L research report →
Companywww.allergytherapeutics.com
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut.
- CEO
- Manuel Llobet
- IPO
- 2004
- Employees
- 612
- HQ
- Worthing, GB
Price Chart
Valuation
- Market Cap
- $477.98M
- P/E
- -10.12
- P/S
- 8.34
- P/B
- 116.57
- EV/EBITDA
- -15.11
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 41.17%
- Op Margin
- -60.23%
- Net Margin
- -85.46%
- ROE
- 409.00%
- ROIC
- -84.29%
Growth & Income
- Revenue
- $55.04M · -0.28%
- Net Income
- $-40,132,000 · 0.21%
- EPS
- $-0.01 · 21.50%
- Op Income
- $-29,505,000
- FCF YoY
- 10.01%
Performance & Tape
- 52W High
- $12.10
- 52W Low
- $6.50
- 50D MA
- $10.46
- 200D MA
- $9.97
- Beta
- 0.89
- Avg Volume
- 245.90K
Get TickerSpark's AI analysis on AGY.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AGY.L Coverage
We haven't published any research on AGY.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AGY.L Report →